SAN DIEGO — In this exclusive video from DDW 2016, Mark Pimentel, MD, from Cedars Sinai Medical Center, discusses the importance of IBSchek, a new blood test for irritable bowel syndrome.
“This biomarker was validated and presented last year at DDW, demonstrating that this antibody panel, anti-CdtB and anti-vinculin, can discriminate IBS from inflammatory bowel disease,” he said. “This would be one of the first biomarkers that says, if you have a patient coming to your office with diarrhea, if you do this, with greater than 95% certainty you have IBS. It’s important for a number of reasons: number one, the patient gets confident diagnosis; number two, IBS could be an organic disease.
“At this DDW, the test went on to be further validated and demonstrated that it is effective in diagnosing IBS-D and IBS-M, but not so well in IBS-C,” he added.
Rezaie A, et al. Abstract #257. Presented at: Digestive Disease Week; May 21-24, 2016; San Diego.
Disclosures: Pimentel reports financial relationships with Salix, Synthetic Biologics, Naia Pharmaceuticals and Commonwealth Labs.